Olmesartanmedoxomil/Hydrochloorthiazide Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: adds diuretic effect to improve blood pressure control.
• Resistant hypertension: provides an additional mechanism when monotherapy is insufficient.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, promoting diuresis. The combined actions result in reduced vascular resistance and decreased plasma volume, leading to lower blood pressure.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Increased urination
• Electrolyte imbalance (low potassium)

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood cell disorders

Before prescribing Olmesartanmedoxomil/Hydrochloorthiazide Sandoz, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: use with caution.
• Electrolyte disturbances: monitor potassium and sodium levels.
• Pregnancy: contraindicated in the second and third trimesters.
• Drug‑specific allergies: avoid if known hypersensitivity to either component.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartanmedoxomil/Hydrochloorthiazide Sandoz can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Potassium‑rich supplements: increase risk of hyperkalemia.
• Aliskiren combined :   ");

Moderate ");

• NSAIDs: may blunt antihypertensive effect.
• Lithium: increased lithium levels.
• ACE inhibitors/ARBs: additive risk of renal dysfunction.
• Antidiabetic drugs: may enhance hypoglycaemic effect.